Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 224

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 224
---
 the caption “Risk Factors” and other information in this Prospectus for a discussion of factors you should carefully consider before deciding to invest in our Common Stock.                                                                                                                              |

| (1) | As of August 13, 2025 |

| (2) | The number of shares                                                                                                              
 of our Common Stock that will be outstanding after this Offering is based on 60,729,100 shares of our Common Stock outstanding as 
 of February 14, 2025 and excludes:                                                                                                |

| ● | 5,200,000                                                                                                                             
 shares of Common stock issuable upon the exercise of outstanding stock options as of August 12_, 2025, granted pursuant to our Global 
 Share Incentive Plan (2021), as amended (the “2021 Plan”), at a weighted-average exercise price of $0.31 per share and                |

| ● | 2,000,000                                                                                                                      
 shares of Common Stock reserved, in the aggregate, for future issuance under our 2021 Plan, as amended, as of August 12, 2025. |

| ● | 6,372,265 shares of Common stock issuable upon the exercise of 6,372,265 warrants, at a weighted-average exercise price of $1.16 per share and |

Except as otherwise indicated, all information in this Prospectus:

<div align='center'>Alt-1

[RESALE PROSPECTUS ALTERNATE PAGE]

SELLING STOCKHOLDERS</div>

This Prospectus relates to the resale,
from time to time, of up to an aggregate of up to 37,625,790 Shares and include (i) 31,253,525 shares of Common Stock of the Company
(which includes 14,479,442 Exchange Shares) and (ii) up to 6,372,265 shares of Common Stock issuable upon exercise of Investor Warrants,
including 4,925,000 shares issuable upon exercise of common stock purchase warrants issued to certain Selling Stockholders at a per share
exercise price of $0.80 and up to 1,447,265 shares issuable upon exercise of common stock purchase warrants issued to certain Selling
Stockholders at a per share exercise price of $2.40.

The Selling Stockholders
are deemed “underwriters” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended.

None of the Selling Stockholders is a registered
broker-dealer or an